The Amyloidosis Channel is supported with funding from Prothena (Silver).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | The promise of CAR-T therapy for the treatment of AL amyloidosis
Carlos Fernandez de Larrea, MD, PhD, University of Barcelona, Barcelona, Spain, discusses the potential use of CAR-T therapy for the treatment of AL amyloidosis and the promise of these agents. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Transcript
That is a very important point, because AL amyloidosis is a disease that is clearly less prevalent than multiple myeloma. In general, we are using treatment for AL amyloidosis that are coming from myeloma treatment. Our first patient in the trial, that was a compassionate use, was treated with our ARI0002h, our CAR-T against BCMA in compassionate use because she had myeloma, but also AL amyloidosis...
That is a very important point, because AL amyloidosis is a disease that is clearly less prevalent than multiple myeloma. In general, we are using treatment for AL amyloidosis that are coming from myeloma treatment. Our first patient in the trial, that was a compassionate use, was treated with our ARI0002h, our CAR-T against BCMA in compassionate use because she had myeloma, but also AL amyloidosis. And even with some toxicities, she achieved a very fast, a stringent complete remission. And she’s still in complete remission, more than 22 months in my patient clinic. Also, with renal response of her amyloidosis.
Read more...
